A Bioequivalence study of a randomized, single dose, two-way crossover design with two-period, two-treatment and two-sequence of AUROLENA 5 (Linagliptin Tablets 5 mg) relative toTRAJENTA film-coated tablets 5 mg in healthy Thai adult volunteers under fasting condition

Start Date25 Sep 2025

Sponsor / Collaborator

Bio-innova Co., Ltd

TCTR20250216006

/ Not yet recruitingPhase 1IIT

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Linagliptin 2.5 mg and Metformin 500 mg Film-coated Tablets relative to Trajenta Duo in Thai healthy volunteers under fed condition

Start Date05 Aug 2025

Sponsor / Collaborator

Bio-innova Co., Ltd

TCTR20250505002

/ Not yet recruitingPhase 1IIT

A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Linagliptin Tablet 5 mgrelative to Trajenta 5 mg Film-coated tablets in healthy Thai volunteers under fasting condition

Start Date25 Jun 2025

Sponsor / Collaborator

Bio-innova Co., Ltd

100 Clinical Results associated with Linagliptin

100 Translational Medicine associated with Linagliptin

100 Patents (Medical) associated with Linagliptin

1,584

Literatures (Medical) associated with Linagliptin

01 Dec 2025·American journal of medicine open

The Association of SGLT2i vs DPP4i on Fracture: A Cohort Study in Veterans with Diabetes

Article

Author: Hackstadt, Amber ; Griffin, Katherine ; Javid, Amir ; Hung, Adriana ; Snyder, Kathryn ; Roumie, Christianne L ; Greevy, Robert

Background:

Increased bone turnover is associated with use of SGLT2i. Patients with diabetes experience adverse effects on bone metabolism. Our aim was to evaluate if SGLT2i was associated with fractures vs DPP4i as add-on therapy to diabetes regimens.

Methods:

We assembled a retrospective cohort of Veterans with diabetes combining Veterans Administration, Medicare, and National Death Index databases. Using an active comparator new user design, patients starting on SGLT2i or DPP4i were followed from prescription fill until a fracture event, death, stopping medication, loss of follow-up, or study end. Fractures included: face/skull, spine, ribs, long bones, hand/feet/digits, or hip. Fractures were identified based on a validated algorithm with positive predictive value 91.3% (86.8, 94.4). Cox models compared the association of fractures between SGLT2i and DPP4i in a propensity score-weighted cohort that balanced 70+ covariates including comorbidities, vital signs, labs, vitamin D levels, smoking, and medications.

Results:

The unweighted sample included 115,124 SGLT2i episodes (104,086 Veterans; 94% empagliflozin; 4% canagliflozin; 2% dapagliflozin) and 213,095 DPP4i episodes (173,724 Veterans; 45% saxagliptin; 15% sitagliptin; 34% alogliptin; 6% Linagliptin). After propensity score calculation and matched weighting, the cohort included 76,072 SGLT2i and 75,833 DPP4i episodes. Median age was 69.3 years and diabetes duration 9.7 (6.1, 14.0) years. In the matched weighted analyses, there were 1431 and 1564 fractures among SGLT2i and DPP4i users, respectively. There were no clinical differences in fractures per 1000 person-years: 18.2 (17.4, 19.1) vs 19.8 (19.0, 20.6). The adjusted hazard ratio (adjusted hazard ratio 0.93 [0.87, 0.99]) excluded increased risk of fractures (adjusted hazard ratio > 1) in SGLT2i users.

Conclusions:

SGLT2i use as add-on treatment for diabetes was not associated with increased fracture outcomes compared to DPP4i.

01 Nov 2025·TALANTA

Erratum to ‘Simultaneous enantiomeric separation of linagliptin and clopidogrel by capillary electrophoresis for the individual, combined, and enantiomeric ecotoxicity evaluation on Pseudokirchneriella subcapitata’ [Talanta (September 2025) 127992]

Author: García, María Ángeles ; Marina, María Luisa ; Boltes, Karina ; García-Cansino, Laura

01 Oct 2025·FREE RADICAL BIOLOGY AND MEDICINE

Targeting the NRF2 pathway with linagliptin to inhibit human hepatocellular carcinoma growth

Article

Author: Chang, Yu-Teng ; Chang, Ming-Jen ; Wu, Ming-Ju ; Shieh, Jeng-Jer ; Chang, Chia-Che

Linagliptin, a potent dipeptidyl peptidase 4 (DPP4) inhibitor, demonstrates significant potential as a therapeutic agent for hepatocellular carcinoma (HCC). This study evaluated the effects of linagliptin on HCC cell lines, focusing on mechanisms involving reactive oxygen species (ROS) production, nuclear factor erythroid 2-related factor 2 (NRF2) pathway activation, and autophagy. Linagliptin effectively suppressed cell proliferation and induced apoptosis in HCC cell lines, particularly Hep3B cells, while sparing normal hepatic cells. It promoted ROS production and activated the NRF2 pathway and autophagy, highlighting a dual role in tumor regulation. Combination therapy with linagliptin and the NRF2 inhibitor brusatol enhanced tumor cell death, suggesting synergistic efficacy. In vivo, linagliptin reduced tumor growth in a xenograft model, with further suppression observed when combined with brusatol. These findings underscore linagliptin's therapeutic potential and its combinatorial efficacy with NRF2 inhibitors, providing a foundation for further clinical investigation in HCC treatment.

News (Medical) associated with Linagliptin

29 Aug 2025

·www.einpresswire.com

July - September 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Ajovy (fremanezumab-vfrm) Emgality (galcanezumab-gnlm) Nurtec ODT (rimegepant) Ubrelvy (ubrogepant) Vyepti (eptinezumab-jjmr) Hypertension The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in March 2025 to include information about the risk of hypertension. Example: Ajovy labeling Apriso (mesalamine) Asacol (mesalamine) Asacol HD (mesalamine) Azulfidine (sulfasalazine) Azulfidine EN-Tabs (sulfasalazine) Canasa (mesalamine) Colazal (balsalazide disodium) Delzicol (mesalamine) Dipentum (osalazine sodium) Giazo (balsalazide disodium) Lialda (mesalamine) Rowasa (mesalamine) Pentasa (mesalamine) Severe cutaneous adverse reactions The Warnings and Precautions section of the labeling was updated November 2021 to include severe cutaneous adverse reactions. Example: Delzicol labeling Avastin (bevacizumab) Mvasi (bevacizumab-awwb) Zirabev (bevacizumab-bvzr) Pancreatitis FDA determined that no action is necessary at the time based on available information. Avastin (bevacizumab) Mvasi (bevacizumab-awwb) Zirabev (bevacizumab-bvzr) Anaphylactic shock The "Warnings and Precautions" section of the labeling was updated between September 2022 and February 2023 to include anaphylactoid/anaphylactic reactions. Example: Avastin labeling Ayvakit (avapritinib) Photosensitivity reaction The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in March 2023 to include information about photosensitivity. Ayvakit labeling Azacitidine Onureg (azacitidine) Vidaza (azacitidine) Generic products containing azacitidine Pericarditis The "Adverse Reactions" section of the labeling was updated between September 2022 and June 2023 to include pericarditis. Example: Vidaza labeling FDA determined that no action is necessary at the time based on available information for Onureg. Bavencio (avelumab) Imfinzi (durvalumab) Libtayo (cemiplimab-rwlc) Keytruda (pembrolizumab) Opdivo (nivolumab) Tecentriq (atezolizumab) Yervoy (ipilimumab) Tumour lysis syndrome FDA determined that no action is necessary at the time based on available information. Cymbalta (duloxetine hydrochloride) Drizalma Sprinkle (duloxetine hydrochloride) Generic products containing duloxetine hydrochloride Anosmia, Hyposmia This issue is posted as two individual newly identified safety signal (NISS) entries in the January-March 2022 quarter, to reflect the focus on the potential signals of anosmia and hyposmia, separately. Darzalex (daratumumab) Darzalex Faspro (daratumumab and hyaluronidase-fihj) Blood stem cell transplant failure FDA determined that no action is necessary at the time based on available information. Dipeptidyl peptidase-4 (DPP-4) inhibitors Glyxambi (empagliflozin and linagliptin) Janumet (metformin hydrochloride and sitagliptin phosphate) Janumet XR (metformin hydrochloride and sitagliptin phosphate) Jentadueto (linagliptin and metformin hydrochloride) Jentadueto XR (linagliptin and metformin hydrochloride) Kazano (alogliptin and metformin hydrochloride) Kombiglyze XR (metformin hydrochloride and saxagliptin) Nesina (alogliptin) Onglyza (saxagliptin) Oseni (alogliptin and pioglitazone) Steglujan (ertugliflozin and sitagliptin) Tradjenta (linagliptin) Trijardy XR (empagliflozin, linagliptin and metformin hydrochloride) Qtern (saxagliptin and dapagliflozin) Generic products containing dipeptidyl peptidase-4 inhibitors Tubulointerstitial nephritis The "Adverse Reactions" section of the labeling was updated between March 2022 and June 2022 for products containing alogliptin and sitagliptin to include tubulointerstitial nephritis. Example: Janumet labeling FDA determined that no action is necessary for products containing linagliptin and saxagliptin at the time based on available information. *An administrative error resulted in the omission of Januvia from the list of product names after the initial quarterly report was posted. Dupixent (dupilumab) Angioedema The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in December 2021 to include angioedema. Dupixent labeling Glucagon-like peptide-1 (GLP-1) analogues Adlyxin (lixisenatide) Bydureon (exenatide) Bydureon BCise (exenatide) Byetta (exenatide) Ozempic (semaglutide) Rybelsus (semaglutide) Saxenda (liraglutide) Soliqua 100/33 (insulin glargine and lixisenatide injection) Trulicity (dulaglutide) Victoza (liraglutide) Wegovy (semaglutide) Xultophy 100/3.6 (insulin degludec and liraglutide injection) Generic products containing glucagon-like peptide-1 analogues Gallbladder related disorders The "Warnings and Precautions", "Adverse Reactions", and "Patient Counseling Information" sections of the GLP-1 analogues labeling were updated between March 2022 and June 2022 to include information about acute gallbladder disease. Example: Adlyxin labeling FDA has determined that the last approved labeling for Saxenda and Wegovy is adequately labeled for acute gallbladder disease, and that no further regulatory action is needed at this time. Gonadotropin releasing hormone (GnRH) analogues Fensolvi (leuprolide acetate) Lupron Depot-PED (leuprolide acetate) Supprelin LA (histrelin acetate) Synarel (nafarelin acetate) Triptodur (triptorelin) Idiopathic intracranial hypertension The "Warnings", "Precautions", and "Adverse Reactions" sections of the labeling were updated in April 2022 to include idiopathic intracranial hypertension. Example: Fensolvi labeling Jakafi (ruxolitinib phosphate) Herpes simplex virus (HSV) reactivation and/or disseminated HSV The "Dosage and Administration", "Warnings and Precautions", and "Adverse Reactions" sections of the labeling were updated in January 2023 to include information about herpes simplex and herpes zoster infections. Jakafi labeling Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (letrozole and ribociclib) Embolic and thrombotic events, venous The "Adverse Reactions" section of the Ibrance labeling was updated in December 2024 to include venous thromboembolism. Ibrance labeling FDA determined that no action is necessary at the time for Kisqali and Kisqali Femara Co-Pack based on available information. Ocrevus (ocrelizumab) Myocardial infarction FDA determined that no action is necessary at the time based on available information. Potassium Chloride Product preparation error The “Warnings” section of the labeling was updated in December 2022 to include information about fatal cardiac adverse reactions with intravenous administration of undiluted potassium chloride. Praxbind (idarucizumab) Wrong dose errors The carton labeling and "Dosage and Administration" sections of the labeling were revised in February 2022 to clarify the number of vials included in each carton and the recommended dosing. Praxbind labeling Qbrexza (glycopyrronium tosylate) Accidental exposure to product The container label, carton labeling, "Dosage and Administration", "Warnings and Precautions", "Patient Counseling Information", and "Patient Information" sections of the labeling were updated in October 2022 to include information about accidental exposure. Qbrexza labeling Qbrexza (glycopyrronium tosylate) Urinary retention The “Warnings and Precautions”, “Adverse Reactions”, and “Patient Counseling Information” sections of the labeling were updated in October 2022 to include information about new or worsening urinary retention. Qbrexza labeling Sodium-glucose cotransporter-2 (SGLT-2) inhibitors Farxiga (dapagliflozin) Glyxambi (empagliflozin and linagliptin) Invokamet (canagliflozin and metformin hydrochloride) Invokamet XR (canagliflozin and metformin hydrochloride) Invokana (canagliflozin) Jardiance (empagliflozin) Qtern (saxagliptin and dapagliflozin) Steglatro (ertugliflozin) Steglujan (ertugliflozin and sitagliptin) Segluromet (ertugliflozin and metformin hydrochloride) Synjardy (empagliflozin and metformin hydrochloride) Synjardy XR (empagliflozin and metformin hydrochloride) Trijardy XR (empagliflozin, linagliptin and metformin hydrochloride) Xigduo XR (dapagliflozin and metformin) Generic products containing sodium-glucose cotransporter-2 (SGLT-2) inhibitors Tubulointerstitial nephritis FDA determined that no action is necessary at the time based on available information. Somatostatin Receptor Imaging Agents Detectnet (copper Cu-64 dotatate injection) Gallium Dotatoc (GA 68) Octreoscan (Indium In 111 Pentetreotide) Netspot (Gallium GA 68 Dotatate) Hypersensitivity The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in December 2021 to include hypersensitivity reactions. Example: Netspot labeling Stromectol (ivermectin) Generic products containing ivermectin Off label use FDA determined that no action is necessary at the time based on available information. Stromectol (ivermectin) Generic products containing ivermectin Neurotoxicity The "Warnings", "Adverse Reactions", and "Overdosage" sections of the labeling were updated in March 2022 to include neurotoxicity. Example: Stromectol labeling Sunosi (solriamfetol hydrochloride) Hypersensitivity FDA determined that no action is necessary at the time based on available information. Vivitrol (naltrexone) Incorrect route of product administration The container label (vial), carton labeling, "Dosage and Administration", "Warnings and Precautions", and "Description", sections of the labeling were revised in September 2022 to emphasize the appropriate route and site of administration. Vivitrol labeling Xcopri (cenobamate) Psychiatric disorders The "Adverse Reactions" section of the labeling was updated in June 2022 to include psychiatric disorders. Xcopri labeling Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

04 Aug 2025

·pharma.economictimes.indiatimes.com

NPPA sets retail prices of 37 drugs; notifies 4 scheduled formulations ceiling price

New Delhi: India’s drug price controller, NPPA has fixed the retail prices of 37 new drug including key type-2 diabetes formulations, antibiotics, cardiac therapies among several others. Issuing a gazette notification, the National Pharmaceutical Pricing Authority (NPPA) announced that the based on the decision of the 135th Authority meeting, the body has fixed retail prices of 37 formulations under Drugs (Prices Control) Order, 2013.” The notified list of 37 formulations includes key diabetes formulations of Empagliflozin, Sitagliptin, Meformin and Linagliptin. Additionally the list comprises formulation of Atorvastatin & Ezetimibe indicated for the treatment of high cholesterol and fats. The list further lunches other common anti-inflammatory formulations and drugs like Paracetamol, Diclofenac among several others. Under the Drugs Price Control Order any marketer, or manufacturers that intends to market a new drug in India is required to obtain a prior approval of the particular drug retail price from the NPPA and in case the fixed price is not complied, then the concerned manufacturer/marketing company is required to deposit the overcharged amount along with an interests per the relevant provision. However, the fixed retail prices are applicable only to the individual manufacturer / marketer who have applied for the same and are specified in the mentioned in the notified list. Meanwhile, in a separate gazette notification the national drug price controller has fixed the ceiling price of four scheduled formulations. The latest notified list includes Ipratropium, Sodium nitroprusside, Povidone iodine, and Diltiazem. Ipratropium is a ‘respirator solution’ indicated for the treatment of condictions like COPD and the drug ceiling price is capped at ₹2.96 per unit. Sodium nitroprusside is an injectable used to control high blood pressure and ceiling price of the formulation is fixed at ₹28.99. The other two scheduled formulations Povidone iodine and Diltiazem are used to treat skin infections and angina (severe chest pain), and the their ceiling price is fixed at ₹6.26 per ml and ₹26.72 per capsule respectively. According to the Ministry of Health and Family Welfare , the National list of Essential Medicines includes those formulations which are indicated for the treatment of diseases which is a public health problem in India, recommended under National Health Programs of India and several other factors. The prices of drugs categorised in the list are fixed and maintained by the NPPA to ensure the affordability of essential drugs for consumers and currently the list includes over 900 formulations. By Online Bureau ,

NDA

09 May 2025

·pharma.economictimes.indiatimes.com

NPPA sets Empagliflozin combos retail prices, as domestic brands initiate generic contest

New Delhi: As domestic brands in India began introducing their generic versions of key anti-diabetic medicine empagliflozin following the expiry of its patent, the National Pharmaceutical Pricing Authority (NPPA), has fixed the retail prices of the drug combinations and different dosage strengths. Issuing a gazette notification, the Ministry of Chemicals and Fertilizers and the country’s drug price regulator announced that “based on the decision of 132nd Authority meeting dated 29.4.2025 the authority has fixed retail prices of 84 formulations under Drugs (Prices Control) Order, 2013.” The price list attached with the official notification includes around 36 variants of empagliflozin, linagliptin and metformin hydrochloride Fixed-Dose Combinations (FDC) of various brands and manufacturers. Empagliflozin, indicated for Type-2 diabetes, inhibits the release of SGLT2 protein in the kidneys which reduces glucose reabsorption in blood and helps in lowering the blood sugar level of patients. Under the notified list the combination of empagliflozin 12.5mg and metformin hydrochloride 1000mg tablet of Corona Remedies is priced at ₹19.64, while a combination including linagliptin along with these active ingredients of Lupin is priced at ₹22.32. The notified retail prices excludes the applicable Goods and Services Tax (GST) and are applicable to the respective manufacturer and marketer specified in the list. As per a market research firm Pharmarack as of April 2025 the total market of empagliflozin and its related combination is valued around ₹745 crore. Of this, plain empagliflozin and its combination with linagliptin accounts for nearly 86 per cent of the total market. In FY25 empagliflozin plain tablets reported a Moving Annual Turnover of ₹337 crore, reflecting a market share of 45 per cent while its combination version with linagliptin had a MAT value of ₹308 crore and a market share of 41 per cent. Besides this the drug's other combinations such as empagliflozin and metformin reported an annual turnover of ₹102 crore with a 14 per cent market share. The retail price fixation exercise has been undertaken in the aftermath of the expiry of empagliflozin’s patent in March this year followed by a series of generic entrants in the market. In India, the drug patent was owned by Germany-based Boehringer Ingelheim and the drug was marketed under the brand name Jardiance. After the drug went off patent, companies like Alkem and Glenmark launched their generic versions under the brand names ‘Empanorm’ and ‘Glempa’ respectively. Besides them other major generic players like Mankind and USV also joined the fray. For patients, the development gave a major price relief as the generic versions are stated to cost around 80-90 per cent less than the patented version. As per the NPPA price list the innovator's version single tablet is priced at ₹53, whereas the other brands from the license holders Torrent, Cipla and Lupin are priced between ₹46-48 per tablet. While announcing the launch, Rajeev Juneja, Vice Chairman and Managing Director, Mankind Pharma said that, “the company will market its respective brand at ₹5.49 per tablet for the 10 mg variant and ₹9.90 per tablet for the 25 mg variant. The latest monthly progress report of Indian pharma market by Pharmarack suggests that as of April close to 147 brands from 37 companies have forayed in the empagliflozin plain and combinations market, reflecting a two-fold jump from the previous month status of 86 brands and 19 Companies. Under the provisions of Drugs (Prices Control) Order, 2013, the retail price of a new drug is fixed by NPPA and the applicant manufacturer and marketer, are required to sell the new drug within the notified price. By Abhijeet Singh ,

100 Deals associated with Linagliptin

External Link

KEGG	Wiki	ATC	Drug Bank
D09566	Linagliptin	A10BH05	DB08882

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	United States	Boehringer Ingelheim Pharmaceuticals, Inc.	02 May 2011

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Stiffness	Phase 3	Netherlands	Boehringer Ingelheim GmbH	01 Mar 2014
Albuminuria	Phase 3	United States	Eli Lilly & Co.	01 Feb 2013
Albuminuria	Phase 3	United States	Boehringer Ingelheim GmbH	01 Feb 2013
Albuminuria	Phase 3	Japan	Eli Lilly & Co.	01 Feb 2013
Albuminuria	Phase 3	Japan	Boehringer Ingelheim GmbH	01 Feb 2013
Albuminuria	Phase 3	Canada	Boehringer Ingelheim GmbH	01 Feb 2013
Albuminuria	Phase 3	Canada	Eli Lilly & Co.	01 Feb 2013
Albuminuria	Phase 3	Denmark	Eli Lilly & Co.	01 Feb 2013
Albuminuria	Phase 3	Denmark	Boehringer Ingelheim GmbH	01 Feb 2013
Albuminuria	Phase 3	Finland	Boehringer Ingelheim GmbH	01 Feb 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03194945 (Literature) Manual	Phase 4	Diabetes Mellitus, Type 2	412	Linagliptin plus Metformin	gubjdlzjhl(pucugoxqvj) = ikhmqecmao ldzdylvgjr (abdfvuvqcb ) View more	Positive	15 Oct 2024
				Linagliptin	gubjdlzjhl(pucugoxqvj) = dsqnvildcz ldzdylvgjr (abdfvuvqcb ) View more
NCT03470454 (Pubmed \| Ren Fail)	Not Applicable	Acute Kidney Injury	800	N-acetyl cysteine and saline	lnjlkuapcl(qxkguffsgi) = fijhcsrbha fvifefxlfb (xjxvooanwd )	-	31 Dec 2023
				Allopurinol	lnjlkuapcl(qxkguffsgi) = igwoymsdhx fvifefxlfb (xjxvooanwd )
NCT04564872 (HSK7653, EASD2023)	Phase 3	Diabetes Mellitus, Type 2 Add-on	-	HSK7653 10mg	jdttncnagn(zmsdjgdkqe) = ifyqbuclny kvqhmycmgk (pnoapwaidr, -1.08 to -0.83)	Positive	03 Oct 2023
				HSK7653 25mg	jdttncnagn(zmsdjgdkqe) = evaqfitkfh kvqhmycmgk (pnoapwaidr, -1.12 to -0.87)
NCT02372630 (1971, CTgov)	Phase 4	Insulin Resistance \| Inflammation \| stress oxidative ... View more	40	Placebo (Placebo)	pudezlnpnx(oxnlwfznvf) = sdbpfumlzv uavysuxjli (xxtfrkzsna, 0.148) View more	-	21 Feb 2023
				Linagliptin (Linagliptin 5mg Per Day)	pudezlnpnx(oxnlwfznvf) = kvamtspqik uavysuxjli (xxtfrkzsna, 0.129) View more
NCT02467478 (CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Renal Insufficiency \| Chronic Kidney Diseases	31	Placebo (Placebo)	wykmlfplfu(imqwqbsdpc) = xsgjorhovh dngflcfhyo (syumvyzxnm, 1.11) View more	-	19 Jan 2023
				Linagliptin (Linagliptin)	wykmlfplfu(imqwqbsdpc) = pmmpudnksw dngflcfhyo (syumvyzxnm, 2.80) View more
NCT01650259 (Pubmed \| Expert Opin Drug Saf)	Not Applicable	Diabetes Mellitus, Type 2	4,876	linagliptin (BMI <25 kg/m2)	nxidnjmcxs(vpungfgtqt) = keqwmxwqdm nikqemjelp (gydvpmbosf ) View more	-	14 Apr 2022
				linagliptin (BMI 25 to <30 kg/m2)	nxidnjmcxs(vpungfgtqt) = juvqpzupjz nikqemjelp (gydvpmbosf ) View more
NCT04542213 (Pubmed \| Sci Rep)	Phase 3	COVID-19	73	Linagliptin + insulin	tzafbjycps(glvqebubwc) = No major side effects were observed oxyxaipqkb (svcnpqgtuy )	Positive	11 Jan 2022
				Insulin alone
NCT04371978 (Pubmed \| Front Endocrinol (Lausanne)) Manual	Phase 3	COVID-19 \| Diabetes Mellitus	64	standard therapy+Linagliptin	wabfokalao(qxaqsftgbj) = jieepaahfb pabljgvdlc (mpavixgkpi, 3.5 - 15) View more	Similar	22 Dec 2021
				standard therapy	wabfokalao(qxaqsftgbj) = akysherlsg pabljgvdlc (mpavixgkpi, 3.5 - 28) View more
NCT02851745 (DYDA 2, Pubmed \| Eur J Prev Cardiol)	Phase 3	Diabetes Mellitus, Type 2	188	Linagliptin 5mg	rytzondstf(kbpxsivyiu) = dlmgiekxts hmbnflozhz (wrcbqpnuvz )	-	23 Mar 2021
				Placebo	rytzondstf(kbpxsivyiu) = vxmpklybxo hmbnflozhz (wrcbqpnuvz )
NCT02897349 (Pubmed \| Diabetes Obes Metab) Manual	Phase 3	Diabetes Mellitus, Type 2	206	linagliptin	odyhbswyvr(dgkgdattke) = gzyamjofoz uavumzvwwb (ckqwbbuqhi ) View more	Positive	01 Feb 2021
				Placebo	odyhbswyvr(dgkgdattke) = gzfwlzbgcq uavumzvwwb (ckqwbbuqhi ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis